Adamas Pharmaceuticals Inc
ADMS
Get informed when a big investor buys or sells
+ FollowMarket Cap$0
Close$
$10.26
24.8% upside
Current Fair Value
24.8% upsideUndervalued by 24.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $0.00 |
|---|---|
| Enterprise Value | $45.94 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.63 |
| Beta | 2.82 |
| Outstanding Shares | 45,618,000 |
Return
| Return on Equity | 290.23% |
|---|---|
| Return on Assets | -43.55% |
| Return on Invested Capital | -32.71% |
Valuation & Multiples
| P/E Ratio | -5.04 |
|---|---|
| PEG | -7.89 |
| Price to Sales | 8.22 |
| Price to Book Ratio | -8.22 |
| Enterprise Value to Revenue | 0.52 |
| Enterprise Value to EBIT | -1.17 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 2.81 |
| Debt to Equity | -5.97 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Adamas Pharmaceuticals Inc
CEO: Neil McFarlane